Plain-English translation of NCT07036380 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing MP0317, a new targeted medication designed to work alongside two standard cancer treatments: an immunotherapy drug called durvalumab and chemotherapy drugs (gemcitabine and cisplatin). Researchers want to see if adding MP0317 helps people with advanced bile duct cancer live longer without their cancer getting worse. The medication works by targeting a special protein found in tumors and activating the immune system to fight cancer more effectively.
Bile duct cancer is a serious disease that is often diagnosed at an advanced stage when it cannot be removed by surgery. Current standard treatments help some patients, but many still experience their cancer growing or spreading. This trial is testing whether this new medication can improve outcomes by working together with existing treatments to help the immune system attack cancer cells more effectively.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive infusions of MP0317 combined with standard chemotherapy and immunotherapy, likely administered at regular clinic visits over several months. You will have blood tests and imaging scans at various points to monitor how the cancer responds and check for side effects. The study will carefully watch for any safety concerns, especially during the first stage, to ensure the treatment is tolerable.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
France